These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30181608)

  • 1. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway.
    Appelman-Dijkstra NM; Papapoulos SE
    Nat Rev Endocrinol; 2018 Oct; 14(10):605-623. PubMed ID: 30181608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The WNT system: background and its role in bone.
    Lerner UH; Ohlsson C
    J Intern Med; 2015 Jun; 277(6):630-49. PubMed ID: 25845559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.
    Martin TJ; Sims NA; Ng KW
    Osteoporos Int; 2008 Aug; 19(8):1125-38. PubMed ID: 18338097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of modulating Wnt signaling pathway toward the development of bone anabolic agent.
    Krause U; Gregory CA
    Curr Mol Pharmacol; 2012 Jun; 5(2):164-73. PubMed ID: 21787289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
    Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
    Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone and Nutrition. Sclerostin and bone metabolism].
    Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
    Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.
    Maeda K; Kobayashi Y; Koide M; Uehara S; Okamoto M; Ishihara A; Kayama T; Saito M; Marumo K
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.
    Rossini M; Gatti D; Adami S
    Calcif Tissue Int; 2013 Aug; 93(2):121-32. PubMed ID: 23748710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anabolic Therapies in Osteoporosis and Bone Regeneration.
    Russow G; Jahn D; Appelt J; Märdian S; Tsitsilonis S; Keller J
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30587780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
    Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building bone to reverse osteoporosis and repair fractures.
    Khosla S; Westendorf JJ; Oursler MJ
    J Clin Invest; 2008 Feb; 118(2):421-8. PubMed ID: 18246192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and pharmacological aspects of existing and experimental bone anabolic therapies.
    Chattopadhyay N
    Curr Mol Pharmacol; 2012 Jun; 5(2):125-6. PubMed ID: 21787294
    [No Abstract]   [Full Text] [Related]  

  • 18. Future therapeutic targets in osteoporosis.
    Deal C
    Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romosozumab: from basic to clinical aspects.
    Minisola S
    Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel strategies for the development of anabolic agents for treatment of osteoporosis].
    Saeki M; Egusa H
    Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):277-80. PubMed ID: 25492363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.